AIM: To investigate impairment and clinical significance of exocrine and endocrine pancreatic function in patients after acute pancreatitis (AP). METHODS: Patients with AP were invited to participate in the study. Severity of AP was determined by the Atlanta classification and definitions revised in 2012. Pancreatic exocrine insufficiency (PEI) was diagnosed by the concentration of fecal elastase-1. An additional work-up, including laboratory testing of serum nutritional markers for determination of malnutrition, was offered to all patients with low levels of fecal elastase-1 FE. Hemoglobin A1c or oral glucose tolerance tests were also performed in patients without prior diabetes mellitus, and type 3c diabetes mellitus (T3cDM) was diagnosed according to American Diabetes Association criteria. RESULTS: One hundred patients were included in the study: 75% (75/100) of patients had one attack of AP and 25% (25/100) had two or more attacks. The most common etiology was alcohol. Mild, moderately severe and severe AP were present in 67, 15 and 18% of patients, respectively. The mean time from attack of AP to inclusion in the study was 2.7 years. PEI was diagnosed in 21% (21/100) of patients and T3cDM in 14% (14/100) of patients. In all patients with PEI, at least one serologic nutritional marker was below the lower limit of normal. T3cDM was more frequently present in patients with severe AP (P = 0.031), but was also present in some patients with mild and moderately severe AP. PEI was present in all degrees of severity of AP. There were no statistically significantly differences according to gender, etiology and number of AP attacks. CONCLUSION: As exocrine and endocrine pancreatic insufficiency can develop after AP, routine follow-up of patients is necessary, for which serum nutritional panel measurements can be useful.
AIM: To investigate impairment and clinical significance of exocrine and endocrine pancreatic function in patients after acute pancreatitis (AP). METHODS:Patients with AP were invited to participate in the study. Severity of AP was determined by the Atlanta classification and definitions revised in 2012. Pancreatic exocrine insufficiency (PEI) was diagnosed by the concentration of fecal elastase-1. An additional work-up, including laboratory testing of serum nutritional markers for determination of malnutrition, was offered to all patients with low levels of fecal elastase-1 FE. Hemoglobin A1c or oral glucose tolerance tests were also performed in patients without prior diabetes mellitus, and type 3c diabetes mellitus (T3cDM) was diagnosed according to American Diabetes Association criteria. RESULTS: One hundred patients were included in the study: 75% (75/100) of patients had one attack of AP and 25% (25/100) had two or more attacks. The most common etiology was alcohol. Mild, moderately severe and severe AP were present in 67, 15 and 18% of patients, respectively. The mean time from attack of AP to inclusion in the study was 2.7 years. PEI was diagnosed in 21% (21/100) of patients and T3cDM in 14% (14/100) of patients. In all patients with PEI, at least one serologic nutritional marker was below the lower limit of normal. T3cDM was more frequently present in patients with severe AP (P = 0.031), but was also present in some patients with mild and moderately severe AP. PEI was present in all degrees of severity of AP. There were no statistically significantly differences according to gender, etiology and number of AP attacks. CONCLUSION: As exocrine and endocrine pancreatic insufficiency can develop after AP, routine follow-up of patients is necessary, for which serum nutritional panel measurements can be useful.
Authors: Michael Elashoff; Aleksey V Matveyenko; Belinda Gier; Robert Elashoff; Peter C Butler Journal: Gastroenterology Date: 2011-02-18 Impact factor: 22.682
Authors: Luigina Bonelli; Hugo Aste; Paolo Bovo; Giorgio Cavallini; Martina Felder; Riccardo Gusmaroli; Erminio Morandini; Paolo Ravelli; Romolo Briglia; Lucio Lombardo; Alberto De Micheli; Vittorio Pugliese Journal: Pancreas Date: 2003-08 Impact factor: 3.327
Authors: Peter A Banks; Thomas L Bollen; Christos Dervenis; Hein G Gooszen; Colin D Johnson; Michael G Sarr; Gregory G Tsiotos; Santhi Swaroop Vege Journal: Gut Date: 2012-10-25 Impact factor: 23.059
Authors: Bonna Leerhøy; Daniel M Shabanzadeh; Andreas Nordholm-Carstensen; Srdan Novovic; Mark B Hansen; Lars N Jørgensen Journal: United European Gastroenterol J Date: 2017-11-09 Impact factor: 4.623
Authors: Richard L Dunbar; Daniel Gaudet; Michael Davidson; Martin Rensfeldt; Hong Yang; Catarina Nilsson; Mats Kvarnström; Jan Oscarsson Journal: Lipids Health Dis Date: 2020-05-30 Impact factor: 3.876
Authors: Alexandra Mikó; Nelli Farkas; András Garami; Imre Szabó; Áron Vincze; Gábor Veres; Judit Bajor; Hussain Alizadeh; Zoltán Rakonczay; Éva Vigh; Katalin Márta; Zoltán Kiss; Péter Hegyi; László Czakó Journal: Pancreas Date: 2018-09 Impact factor: 3.327
Authors: Wei Huang; Daniel de la Iglesia-García; Iria Baston-Rey; Cristina Calviño-Suarez; Jose Lariño-Noia; Julio Iglesias-Garcia; Na Shi; Xiaoying Zhang; Wenhao Cai; Lihui Deng; Danielle Moore; Vikesh K Singh; Qing Xia; John A Windsor; J Enrique Domínguez-Muñoz; Robert Sutton Journal: Dig Dis Sci Date: 2019-06-04 Impact factor: 3.487
Authors: Pedram Paragomi; Anna Evans Phillips; Jorge D Machicado; Ali Lahooti; Ayesha Kamal; Elham Afghani; Ioannis Pothoulakis; Shari L Reynolds; Melanie Mays; Darwin L Conwell; Luis F Lara; Vikesh K Singh; Georgios I Papachristou Journal: Pancreas Date: 2021-02-01 Impact factor: 3.243